JPWO2020234432A5 - - Google Patents

Info

Publication number

JPWO2020234432A5

JPWO2020234432A5 JP2021569042A JP2021569042A JPWO2020234432A5 JP WO2020234432 A5 JPWO2020234432 A5 JP WO2020234432A5 JP 2021569042 A JP2021569042 A JP 2021569042A JP 2021569042 A JP2021569042 A JP 2021569042A JP WO2020234432 A5 JPWO2020234432 A5 JP WO2020234432A5

Authority

JP

Japan

Prior art keywords

neuropathy

pharmaceutical composition

seq

amino acid

acid sequence

Prior art date

2023-05-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 208000033808 peripheral neuropathy Diseases 0.000 claims description 26
• 239000000427 antigen Substances 0.000 claims description 23
• 102000036639 antigens Human genes 0.000 claims description 23
• 108091007433 antigens Proteins 0.000 claims description 23
• 201000001119 neuropathy Diseases 0.000 claims description 23
• 239000012634 fragment Substances 0.000 claims description 21
• 230000007823 neuropathy Effects 0.000 claims description 21
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
• 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 11
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 7
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 7
• 230000024203 complement activation Effects 0.000 claims description 7
• 150000002270 gangliosides Chemical class 0.000 claims description 6
• 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims description 4
• 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims description 4
• 208000027137 acute motor axonal neuropathy Diseases 0.000 claims description 4
• 230000003210 demyelinating effect Effects 0.000 claims description 4
• 230000001537 neural effect Effects 0.000 claims description 4
• 208000011580 syndromic disease Diseases 0.000 claims description 4
• 206010003591 Ataxia Diseases 0.000 claims description 2
• 108060003951 Immunoglobulin Proteins 0.000 claims description 2
• 102000004856 Lectins Human genes 0.000 claims description 2
• 108090001090 Lectins Proteins 0.000 claims description 2
• 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 2
• 206010053869 POEMS syndrome Diseases 0.000 claims description 2
• 208000002774 Paraproteinemias Diseases 0.000 claims description 2
• 230000001154 acute effect Effects 0.000 claims description 2
• 208000027094 acute motor and sensory axonal neuropathy Diseases 0.000 claims description 2
• 230000001977 ataxic effect Effects 0.000 claims description 2
• 206010003882 axonal neuropathy Diseases 0.000 claims description 2
• 230000001684 chronic effect Effects 0.000 claims description 2
• 102000018358 immunoglobulin Human genes 0.000 claims description 2
• 229940072221 immunoglobulins Drugs 0.000 claims description 2
• 230000003155 kinesthetic effect Effects 0.000 claims description 2
• 239000002523 lectin Substances 0.000 claims description 2
• 206010030875 ophthalmoplegia Diseases 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 16
• 238000000034 method Methods 0.000 description 32
• 239000005557 antagonist Substances 0.000 description 13
• 230000000295 complement effect Effects 0.000 description 12
• 230000004154 complement system Effects 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 4
• 238000011144 upstream manufacturing Methods 0.000 description 3
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 2
• 210000002161 motor neuron Anatomy 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
• 229940125990 ANX005 Drugs 0.000 description 1
• 102100022002 CD59 glycoprotein Human genes 0.000 description 1
• 101100268548 Caenorhabditis elegans apl-1 gene Proteins 0.000 description 1
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
• 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 108091027967 Small hairpin RNA Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 101900335902 Vaccinia virus Complement control protein C3 Proteins 0.000 description 1
• 229940088949 cinryze Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 239000003814 drug Substances 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 102000034356 gene-regulatory proteins Human genes 0.000 description 1
• 108091006104 gene-regulatory proteins Proteins 0.000 description 1
• 102000044507 human SERPING1 Human genes 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical compound C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 description 1
• 229950009865 nafamostat Drugs 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 239000004055 small Interfering RNA Substances 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1